Elanco Animal Health (ELAN) Income from Continuing Operations (2017 - 2026)
Elanco Animal Health (ELAN) posted Income from Continuing Operations of 57000000.0 for Q1 2026, up 120.65% sequentially from 276000000.0 in Q4 2025, and down 14.93% YoY from 67000000.0 in Q1 2025.
Elanco Animal Health (ELAN) Income from Continuing Operations (2017 - 2026) Analysis & Trends
Elanco Animal Health has reported Income from Continuing Operations for 10 years, with the latest figure at 57000000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 14.93% year-over-year to 57000000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 242000000.0 (down 164.88% YoY) and the FY2025 annual result came in at 232000000.0, down 168.64% from the prior year.
- Income from Continuing Operations advanced to 57000000.0 in Q1 2026 per ELAN's latest filing, from 276000000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 364000000.0 in Q3 2024 and troughed at 1096000000.0 in Q3 2023.
- A 5-year average of 67411764.71 and a median of 10000000.0 in 2022 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2025: Income from Continuing Operations jumped 179.69% in 2022, then sank 3350.0% in 2025.
- Over 5 years, Income from Continuing Operations stood at 54000000.0 in 2022, then slumped by 161.11% to 141000000.0 in 2023, then soared by 94.33% to 8000000.0 in 2024, then tumbled by 3350.0% to 276000000.0 in 2025, then jumped by 120.65% to 57000000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 57000000.0, 276000000.0, and 34000000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.80 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.05 Bn | 39.39 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.51 Bn | 29.84 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.70 Bn | 22.90 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.83 Bn | 17.95 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 12.06 Bn | 11.53 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | - |
| 10 | Alkermes | 8.27 Bn | 7.61 Bn | 397.90 Mn | 524,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 54.00 Mn |
| Mar 31, 2026 | 57.00 Mn |
| Dec 31, 2025 | -276.00 Mn |
| Sep 30, 2025 | -34.00 Mn |
| Jun 30, 2025 | 11.00 Mn |
| Mar 31, 2025 | 67.00 Mn |
| Dec 31, 2024 | -8.00 Mn |
| Sep 30, 2024 | 364.00 Mn |
| Jun 30, 2024 | -50.00 Mn |
| Mar 31, 2024 | 32.00 Mn |
| Dec 31, 2023 | -141.00 Mn |
| Sep 30, 2023 | -1.10 Bn |
| Jun 30, 2023 | -97.00 Mn |
| Mar 31, 2023 | 103.00 Mn |
| Dec 31, 2022 | -54.00 Mn |
| Sep 30, 2022 | -65.00 Mn |
| Jun 30, 2022 | -10.00 Mn |
| Mar 31, 2022 | 51.00 Mn |
| Dec 31, 2021 | -105.00 Mn |
| Sep 30, 2021 | -108.00 Mn |